Internship

Intern – Corporate Development

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Work full-time on site from Cytokinetics’ South San Francisco headquarters.

Category
Public Health
Biology Lab & Research
Biology & Biotech

You match the following Cytokinetics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • College or graduate student, with responsibilities tailored accordingly
  • Work full-time on site from Cytokinetics’ South San Francisco headquarters
  • Positive attitude, attention to detail and interest in helping others
  • Team player with strong interpersonal and communication skills
  • Biological knowledge necessary to understand the drug pipeline/portfolio of Cytokinetics and potential partners
  • Excellent analytical capabilities required
  • Ability to summarize or simplify complex concepts in words and graphics and to “think on your feet”
Responsibilities
  • Assist the team responsible for identifying and evaluating licensing and collaboration opportunities and negotiating term sheets and agreements
  • Perform background research on potential partners, including public and proprietary database searches
  • Update internal tracking documents to ensure all information accurately reflects the current situation
  • Support initiatives to enhance alliance management capabilities
  • Inform Cytokinetics’ cross-functional strategic planning
  • Generate and deliver impactful presentations to senior management and key decision-makers

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a range of drugs in clinical trials, including omecamtiv mecarbil and reldesemtiv, aimed at treating conditions like heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from debilitating muscle-related conditions.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

-5%

2 year growth

-2%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent investments indicate strong interest in muscle activators and inhibitors.
  • Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
  • Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

What critics are saying

  • Increased competition could impact market share and profitability.
  • Potential delays in clinical trials could hinder drug commercialization.
  • Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company has a robust pipeline including omecamtiv mecarbil and aficamten.
  • Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Help us improve and share your feedback! Did you find this helpful?